Cited by 26Acute Lymphoblastic Leukemia researchLymphoma Diagnosis and TreatmentCAR-T cell therapy research

A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization.

Yetgin, Sevgi, Gürgey, Aytemiz, Murat Tuncer, A, Çetin, Mualla, Özbek, Namik, Şayli, Tülin, Güler, Ertuğrul, Kara, Abdurrahman +5 more·1998·Leukemia Research

Abstract

In this preliminary study the efficacy of high-dose methylprednisolone (HDMP) during remission-induction chemotherapy was evaluated on 166 children with acute lymphoblastic leukemia (ALL). The St. Jude Total Therapy Study XI protocol with minor modifications was used in this trial. Patients were randomized into two groups. Group A received conventional-dose (2 mg/kg/day orally) prednisolone, and group B received high-dose methylprednisolone (HDMP, Prednol-L, 900-600 mg/m2 orally) during remission-induction chemotherapy. Complete remission was achieved in 97% of the children. For the 80 patients who were followed up for 3 years, median follow-up was 44 (range 5-60) months and the 3-year event-free survival (EFS) rate was 68.5%) overall, 58.6% in group A and 78.4% in group B. The EFS among patients in group B was significantly higher than in group A (p=0.05). When we compared the 3-year EFS of groups A and B in the high-risk groups and high-risk subgroups with white blood cell (WBC) counts > or = 50 x 10(9)/l and age > or = 10 years, the survival rates were 45% versus 77.2%, 33% versus 78% and 45% versus 89%, respectively. During the follow-up of 162 patients, relapses were significantly higher in group A. Bone marrow relapses in 162 patients, and also in a subgroup of patients > or = 10 years of age were significantly higher in group A. These results suggest that HDMP during remission-induction chemotherapy improves long-term EFS, particularly for high-risk patients.

Integrity signals

Registry

Crossref · 10.1016/s0145-2126(98)00003-4

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yetgin, S., Gürgey, A., Murat Tuncer, A., Çetin, M., Özbek, N., Şayli, T., Güler, E., Kara, A., Olcay, L., Duru, F., Gümrük, F., Atahan, L., & Tunçbilek, E.
Affiliations
  • Hacettepe University (TR)
  • Hacettepe University Hospital (TR)
Corresponding author
Yetgin, Sevgi
Venue
Leukemia Research
Publisher
Elsevier BV
Published
1998-06
Volume
22
Issue
6
Pages
485-493
ISSN
0145-2126 (ISSN-L)
OpenAlex
W2053130412
Cited by
26
References
35
Citations by year
2024: 1 · 2015: 1 · 2014: 2 · 2012: 1
FWCI
1.74
Type
journal article
Language
en
Open access
closed
Locations
  • Leukemia Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
high-dose methylprednisolone, prednisolone, acute lymphoblastic leukemia, pediatric leukemia, induction chemotherapy, event-free survival, relapse, high-risk patients, glucocorticoids
MeSH terms
Adolescent, Age Factors, Antineoplastic Agents, Child, Child, Preschool, Dose-Response Relationship, Drug, Female, Humans, Infant, Infections, Leukocyte Count, Male, Methylprednisolone, Neutropenia, Prednisolone, Recurrence, Remission Induction, Risk Factors, Time Factors, Leukemia, Myeloid, Acute, Survival Rate, Disease-Free Survival, Precursor Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review